TGRX-1942 study for advanced solid tumor or blood cancer
Part of Blood & lymphatic, Cancer, Lungs & breathing clinical trials.
This trial tests an experimental drug (TGRX-1942) for people with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The main goal is to find a safe dose and see how well the drug works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced solid tumor cancer or relapsed blood cancer that has not responded to standard treatments and no other effective options.
- You are able to do most daily activities without help (ECOG 0 or 1).
- Your life expectancy is at least 3 months.
- Your blood counts and liver, kidney function are adequate.
- You agree to provide a tumor biopsy sample (or recent report) and to donate blood samples.
- If you or your partner can become pregnant, you agree to use effective birth control during and for 2 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called TGRX-814 for people with certain blood cancers like non-Hodgkin's lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, or myelodysplastic syndromes. It aims to see if the drug is safe and effective.
This trial tests a new drug called TRX-920 for people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The goal is to see if TRX-920 is safe and effective.
This is an early-stage study testing a new drug called GTB-5550 in people with advanced cancers that have spread. The study aims to find the right dose and see if the drug helps shrink tumors.
This early-phase trial studies TR64 in people with advanced solid cancers when standard treatments have stopped working or aren’t an option. It aims to see whether the drug can reduce tumors and is safe enough to keep studying.
This Phase 1/2 study tests an experimental medicine (RNK05047) in people with advanced solid tumors or diffuse large B‑cell lymphoma whose standard treatments haven’t worked or can’t be tolerated. It may help shrink tumors and improve control of the disease, but early-phase trials also focus on safety and dosing.
This study tests a new drug (BGB-26808) alone or with another drug (tislelizumab) for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if the combination can help shrink tumors or slow their growth.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.